Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
self-efficacy related to exercise (Bandura's Exercise Self-efficacy) |
Using Bandura's Exercise Self-efficacy to determine the effects of TecHCR on self-efficacy related to exercise before intervention (baseline) |
Baseline (T0) - at 0 week, before initiation of interventions |
|
Primary |
self-efficacy related to exercise (Bandura's Exercise Self-efficacy) |
Using Bandura's Exercise Self-efficacy to determine the effects of TecHCR on self-efficacy related to exercise post intervention (at 3-month) |
post intervention (T1) - at 12 weeks after initiation of interventions |
|
Primary |
self-efficacy related to exercise (Bandura's Exercise Self-efficacy) |
Using Bandura's Exercise Self-efficacy to determine the effects of TecHCR on self-efficacy related to exercise 3-month post intervention (T2) (at 6 month) |
6-month post intervention (T2) - at 36 weeks after initiation of interventions |
|
Secondary |
behavioural outcomes (Health-promoting Lifestyle Profile II) |
Using Health-promoting lifestyle Profile II to determine the effects of TecHCR on health promoting behaviours |
Baseline (T0) - at 0 week, before initiation of interventions |
|
Secondary |
behavioural outcomes (Health-promoting Lifestyle Profile II) |
Using Health-promoting lifestyle Profile II to determine the effects of TecHCR on health promoting behaviours |
post intervention (T1) - at 12 weeks after initiation of interventions |
|
Secondary |
behavioural outcomes (Health-promoting Lifestyle Profile II) |
Using Health-promoting lifestyle Profile II to determine the effects of TecHCR on health promoting behaviours |
6-month post intervention (T2) - at 36 weeks after initiation of interventions |
|
Secondary |
psychological outcomes (Hospital Anxiety and Depression Scale) |
Using Hospital Anxiety and Depression Scale to determine the effects of TecHCR on anxiety and depression |
Baseline (T0) - at 0 week, before initiation of interventions |
|
Secondary |
psychological outcomes (Hospital Anxiety and Depression Scale) |
Using Hospital Anxiety and Depression Scale to determine the effects of TecHCR on anxiety and depression |
post intervention (T1) - at 12 weeks after initiation of interventions |
|
Secondary |
psychological outcomes (Hospital Anxiety and Depression Scale) |
Using Hospital Anxiety and Depression Scale to determine the effects of TecHCR on anxiety and depression |
6-month post intervention (T2) - at 36 weeks after initiation of interventions |
|
Secondary |
fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (from laboratory blood test result) |
to determine the effects of TecHCR on fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (mmol/L) |
Baseline (T0) - at 0 week, before initiation of interventions |
|
Secondary |
fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (from laboratory blood test result) |
to determine the effects of TecHCR on fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (mmol/L) |
post intervention (T1) - at 12 weeks after initiation of interventions |
|
Secondary |
fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (from laboratory blood test result) |
to determine the effects of TecHCR on fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (mmol/L) |
6-month post intervention (T2) - at 36 weeks after initiation of interventions |
|
Secondary |
systolic and diastolic blood pressure (using blood pressure monitoring device) |
to determine the effects of TecHCR on systolic and diastolic blood pressure |
Baseline (T0) - at 0 week, before initiation of interventions |
|
Secondary |
systolic and diastolic blood pressure (using blood pressure monitoring device) |
to determine the effects of TecHCR on systolic and diastolic blood pressure |
post intervention (T1) - at 12 weeks after initiation of interventions |
|
Secondary |
systolic and diastolic blood pressure (using blood pressure monitoring device) |
to determine the effects of TecHCR on systolic and diastolic blood pressure |
6-month post intervention (T2) - at 36 weeks after initiation of interventions |
|
Secondary |
Body Mass Index (BMI) (weight in kilogrammes*height in metres^2) |
to determine the effects of TecHCR on BMI |
Baseline (T0) - at 0 week, before initiation of interventions |
|
Secondary |
Body Mass Index (BMI) (weight in kilogrammes*height in metres^2) |
to determine the effects of TecHCR on BMI |
post intervention (T1) - at 12 weeks after initiation of interventions |
|
Secondary |
Body Mass Index (BMI) (weight in kilogrammes*height in metres^2) |
to determine the effects of TecHCR on BMI |
6-month post intervention (T2) - at 36 weeks after initiation of interventions |
|
Secondary |
Waist circumference (measured by measuring tape in centimetres) |
to determine the effects of TecHCR on waist circumference |
Baseline (T0) - at 0 week, before initiation of interventions |
|
Secondary |
Waist circumference (measured by measuring tape in centimetres) |
to determine the effects of TecHCR on waist circumference |
post intervention (T1) - at 12 weeks after initiation of interventions |
|
Secondary |
Waist circumference (measured by measuring tape in centimetres) |
to determine the effects of TecHCR on waist circumference |
6-month post intervention (T2) - at 36 weeks after initiation of interventions |
|